Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Jazz Pharmaceuticals (JAZZ) PT Lowered to $190 at Stifel Following 4Q
March 1, 2017 9:00 AM ESTStifel lowered its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $190.00 (from $200.00) while maintaining a Buy rating.
Analyst Annabel Samimy commented, "JAZZ reported 4Q16 revenue of $396.6mn (Cons. $398.3mn), representing +16.4% y/y. Top-line was driven by Xyrem with sales of $291.2mn (Cons.... More
